Open AccessProspective studies of infectious mononucleosis in university students
Author(s) -
Grimm Jennifer M,
Schmeling David O,
Dunmire Samantha K,
Knight Jennifer A,
Mullan Beth D,
Ed Julie A,
Brundage Richard C,
Hogquist Kristin A,
Balfour Henry H
Publication year - 2016
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1038/cti.2016.48
Subject(s) - mononucleosis , antibody , immunology , medicine , epstein–barr virus , virus , epstein–barr virus infection , prospective cohort study , risk factor , virology
We performed an intensive prospective study designed to obtain as much data as possible on the incubation and early illness periods of primary Epstein–Barr virus (EBV) infection. Undergraduate students who lacked EBV antibody and oral EBV DNA (EBV‐naive) were seen every 2 weeks during their freshman year. Clinical and behavioral data, oral washes and venous blood were obtained. EBV antibodies were quantified by enzyme immunoassay and viral loads by PCR. During a median 8 months of observation, 14/85 subjects experienced primary EBV infections (24 cases/100 person‐years). The only significant risk factor for acquisition of EBV infection was deep kissing ( P =0.02). Eleven subjects had infectious mononucleosis with a median duration of 21 days. Two subjects were hospitalized. Infections were initially identified in 12 subjects by finding EBV DNA in oral cells before onset of symptoms and in 2 subjects by symptom reporting. EBV DNA and viral capsid antigen (VCA) IgM and gp350 IgG antibodies were present in the blood before onset of illness. To provide a more robust evaluation of primary EBV infection in undergraduate university students, we combined data on risk factors and antibody responses from this and an earlier study that used the exact same clinical and laboratory methods. The observation that the only significant risk factor for acquisition of EBV infection was deep kissing was confirmed. Most importantly, higher amounts of gp350 antibody correlated significantly with a lower severity of infectious mononucleosis ( P <0.0001), which strengthens the rationale for a gp350‐based prophylactic EBV vaccine.